A very recent phase II clinical trial (NCT01882985) investigated the activity of docetaxel chemotherapy plus lycopene in advanced castrate-resistant adenocarcinoma of the prostate with a ≥50% reduction in PSA, median time to PSA progression, duration of response, and overall survival as the principal endpoints [89] (Table 1). Here, KLK3 is linked to prostate adenocarcinoma.